Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fostamatinib disodium Clear all

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib Disodium (R935788); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 35
States / cities: La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more

Conditions: Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Interventions: Fostamatinib disodium; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more

Conditions: Drug Drug Interactions, Healthy Volunteers
Interventions: FOSTAMATIN, Verapamil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more

Conditions: Healthy
Interventions: FosD, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: T Cell Lymphoma
Interventions: Fostamatinib Disodium; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions: Fostamatinib, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib disodium (R935788), Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Aventura, California • Palm Desert, California • San Diego, California + 24 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib disodium; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more

Conditions: ITP, Immune Thrombocytopenia
Interventions: Fostamatinib; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib Disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nyack, New York

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib 150 mg bid; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 31
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 27 more

Conditions: Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib Disodium; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: Fostamatinib Disodium / R935788; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Search by objective public record fields.

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)